25 research outputs found

    Global increases in both common and rare copy number load associated with autism.

    Get PDF
    Children with autism have an elevated frequency of large, rare copy number variants (CNVs). However, the global load of deletions or duplications, per se, and their size, location and relationship to clinical manifestations of autism have not been documented. We examined CNV data from 516 individuals with autism or typical development from the population-based Childhood Autism Risks from Genetics and Environment (CHARGE) study. We interrogated 120 regions flanked by segmental duplications (genomic hotspots) for events >50 kbp and the entire genomic backbone for variants >300 kbp using a custom targeted DNA microarray. This analysis was complemented by a separate study of five highly dynamic hotspots associated with autism or developmental delay syndromes, using a finely tiled array platform (>1 kbp) in 142 children matched for gender and ethnicity. In both studies, a significant increase in the number of base pairs of duplication, but not deletion, was associated with autism. Significantly elevated levels of CNV load remained after the removal of rare and likely pathogenic events. Further, the entire CNV load detected with the finely tiled array was contributed by common variants. The impact of this variation was assessed by examining the correlation of clinical outcomes with CNV load. The level of personal and social skills, measured by Vineland Adaptive Behavior Scales, negatively correlated (Spearman's r = -0.13, P = 0.034) with the duplication CNV load for the affected children; the strongest association was found for communication (P = 0.048) and socialization (P = 0.022) scores. We propose that CNV load, predominantly increased genomic base pairs of duplication, predisposes to autism

    Chaco Canyon Dig Unearths Ethical Concerns

    Get PDF
    The field of paleogenomics (the study of ancient genomes) is rapidly advancing with more robust methods of isolating ancient DNA and increasing access to next-generation DNA sequencing technology. As these studies progress, many important ethical issues have emerged that should be considered when ancient Native American remains, whom we refer to as ancestors, are used in research. We highlight a recent article by Kennett et al. (2017), “Archaeogenomic evidence reveals prehistoric matrilineal dynasty,” that brings several ethical issues to light that should be addressed in paleogenomics research (Kennett et al. 2017). The study helps elucidate the matrilineal relationships in ancient Chacoan society through ancient DNA analysis. However, we, as Indigenous researchers and allies, raise ethical concerns with the study’s scientific conclusions that can be problematic for Native American communities: (1) the lack of tribal consultation, (2) the use of culturally-insensitive descriptions, and (3) the potential impact on marginalized groups. Further, we explore the limitations of the Native American Graves Protection and Repatriation Act (NAGPRA), which addresses repatriation but not research, as clear ethical guidelines have not been established for research involving Native American ancestors, especially those deemed “culturally unaffiliated”. As multiple studies of culturally unaffiliated remains have been initiated recently, it is imperative that researchers consider the ethical ramifications of paleogenomics research. Past research indiscretions have created a history of mistrust and exploitation in many Native American communities. To promote ethical engagement of Native American communities in research, we therefore suggest careful attention to the ethical considerations, strong tribal consultation requirements, and greater collaborations amongst museums, federal agencies, researchers, scientific journals, and granting agencies

    Imputation of Exome Sequence Variants into Population- Based Samples and Blood-Cell-Trait-Associated Loci in African Americans: NHLBI GO Exome Sequencing Project

    Get PDF
    Researchers have successfully applied exome sequencing to discover causal variants in selected individuals with familial, highly penetrant disorders. We demonstrate the utility of exome sequencing followed by imputation for discovering low-frequency variants associated with complex quantitative traits. We performed exome sequencing in a reference panel of 761 African Americans and then imputed newly discovered variants into a larger sample of more than 13,000 African Americans for association testing with the blood cell traits hemoglobin, hematocrit, white blood count, and platelet count. First, we illustrate the feasibility of our approach by demonstrating genome-wide-significant associations for variants that are not covered by conventional genotyping arrays; for example, one such association is that between higher platelet count and an MPL c.117G>T (p.Lys39Asn) variant encoding a p.Lys39Asn amino acid substitution of the thrombpoietin receptor gene (p = 1.5 × 10−11). Second, we identified an association between missense variants of LCT and higher white blood count (p = 4 × 10−13). Third, we identified low-frequency coding variants that might account for allelic heterogeneity at several known blood cell-associated loci: MPL c.754T>C (p.Tyr252His) was associated with higher platelet count; CD36 c.975T>G (p.Tyr325∗) was associated with lower platelet count; and several missense variants at the α-globin gene locus were associated with lower hemoglobin. By identifying low-frequency missense variants associated with blood cell traits not previously reported by genome-wide association studies, we establish that exome sequencing followed by imputation is a powerful approach to dissecting complex, genetically heterogeneous traits in large population-based studies

    Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility

    Get PDF
    Fasting glucose and insulin are intermediate traits for type 2 diabetes. Here we explore the role of coding variation on these traits by analysis of variants on the HumanExome BeadChip in 60,564 non-diabetic individuals and in 16,491 T2D cases and 81,877 controls. We identify a novel association of a low-frequency nonsynonymous SNV in GLP1R (A316T; rs10305492; MAF=1.4%) with lower FG (β=−0.09±0.01 mmol l−1, P=3.4 × 10−12), T2D risk (OR[95%CI]=0.86[0.76–0.96], P=0.010), early insulin secretion (β=−0.07±0.035 pmolinsulin mmolglucose−1, P=0.048), but higher 2-h glucose (β=0.16±0.05 mmol l−1, P=4.3 × 10−4). We identify a gene-based association with FG at G6PC2 (pSKAT=6.8 × 10−6) driven by four rare protein-coding SNVs (H177Y, Y207S, R283X and S324P). We identify rs651007 (MAF=20%) in the first intron of ABO at the putative promoter of an antisense lncRNA, associating with higher FG (β=0.02±0.004 mmol l−1, P=1.3 × 10−8). Our approach identifies novel coding variant associations and extends the allelic spectrum of variation underlying diabetes-related quantitative traits and T2D susceptibility. Both rare and common variants contribute to the aetiology of complex traits such as type 2 diabetes (T2D). Here, the authors examine the effect of coding variation on glycaemic traits and T2D, and identify low-frequency variation in GLP1R significantly associated with these traits

    Next Generation ABO Genetics and Genomics

    No full text
    Thesis (Ph.D.)--University of Washington, 2016-08Accurately cross matching units of blood based on blood type is essential for successful transfusion therapy. ABO is the most clinically relevant blood group in transfusion therapy due to the presence of naturally occurring ABO antibodies. Failure to correctly match ABO blood type can cause fatal transfusion reactions even in transfusion naïve individuals. The ABO gene commonly encodes two different forms of a glycosyltransferase which adds A or B sugars (N-acetylgalactosamine for A or α-D-galactose for B) to the H-antigen substrate. Single nucleotide variants (SNVs) and insertion-deletions (indels) in the ABO gene affect function at the molecular level by altering the specificity and efficiency of the enzyme for specific sugars (leading to the A1, A2, and B blood types) or by knocking out gene function to generate the O blood type. Thus, variation in A, B, or O serological phenotype is the result of genetic variation in the coding portion of the ABO gene. Currently, approaches to genotype ABO are limited because ABO is a complex locus with a large number of functional haplotypes that can lead to the A, B, or O phenotype. In addition to many other factors, ABO blood type plays a role in determining an individual’s risk for multiple common complex diseases including the number one and number two causes of death in the United States: cardiovascular disease and cancer. However, the influence of specific ABO types and ABO subtype variants, such as the A1 and A2 haplotype/subtypes, on common complex disease risk has not yet been fully explored. In this dissertation, I directly explore the many forms of variation in the ABO gene in diverse human populations using multiple next-generation human genome sequencing datasets, while simultaneously addressing the limitations of both traditional serological methods and existing genotyping methods designed to determine ABO blood type from variation found in the ABO gene. I then discuss strategies and limitations of developing an automated approach to call high resolution phased ABO blood types from NGS data. The methods and analyses outlined in this dissertation can be used to generate higher resolution blood type and subtype calls leveraging the variation and phenotypes within large scale NGS populations based to explore the relationships between rare and common ABO variants, ABO haplotypes, and subtypes with common complex disease relatedphenotypes (i.e., cardiovascular disease, cancer, and type 2 diabetes). My hope is that the NGS tools developed in this thesis will be used to create a more comprehensive understanding of common complex disease etiology in the future
    corecore